AB Science SA's shotgun approach to drug development appears to have scored another late-stage win. Just months after reporting positive phase III data with tyrosine kinase inhibitor masitinib in mastocytosis, the Paris-based firm disclosed interim results from a phase III study in which the drug met the primary objective in amyotrophic lateral sclerosis (ALS), a condition that has been littered with failure in the past two decades.